Navigation Links
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
Date:8/14/2015

Dr Robert Harman (DVM), Founder and CEO of Regenerative Veterinary Medicine company VetStem Biopharma, Inc. is scheduled to be a guest speaker at MSC 2015 Innovations in Cell-Based Regenerative Therapies in Cleveland, OH along with Dr Jamie Gaynor (DVM, DACVA, DACVPM) and Dr Scott Gustafson (DVM, DACVS).

The conference will offer a forum for the scientific exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The topics that will be covered in this conference range from basic discovery through model validation, clinical product development, and therapeutic application. Dr. Harman is scheduled to present on August 19th along with Dr Gaynor and Dr Gustafson. They will be presenting on Mesenchymal Stem Cell’s in Veterinary Medicine.

Dr Harman pulls from his biotechnology and veterinary experience to help VetStem perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development for regenerative medicine in the veterinary field, with over 11,000 animals treated in the last 12 years.

Dr. Gaynor, a noted anesthesiologist and pain management specialist, has been involved in Regenerative Medicine since 2006. He has treated over 100 patients and been involved in three canine studies in the use of MSC’s for the treatment of osteoarthritis. Dr Gaynor has lectured nationally on the use of stem cells in veterinary medicine.

Dr. Gustafson has lectured nationally in stem cell therapy and has performed clinical stem cell therapy for 7 years. In 2007 Dr. Gustafson was credentialed with VetStem, in the use of Regenerative Veterinary Medicine for arthritis, ligament and tendon injuries, and joint. To date he has provided over 50 stem cell treatments for dogs. He has also participated in VetStem’s clinical trials.

VetStem first pioneered stem cell therapy for use in horses for tendon injuries, as an alternative to other choices such as euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog.

In 2007 the first peer reviewed, randomized, double-blinded, placebo controlled, multi-center study was published proving intra-articular injection of VetStem processed adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal small animal stem cell credentialing course. In 2015, VetStem (now VetStem Biopharma) has announced the successful completion of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INAD. Primary end point was statistically significant. The study will be submitted for peer reviewed publication.

“The opportunity to speak at such a prestigious conference is an honor and further recognition by the human regenerative medicine community of the significant progress and insights we (veterinarians) have contributed to the field of regenerative medicine over the past 12 years, with over 11,000 animal patients treated”, stated Dr Harman.

About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, Vet-Stem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Contact:
Kristi Hauta
Marketing Operations Manager
VetStem Biopharma
khauta(at)vetstem(dot)com
Ph (858) 748-2004 ext 208
12860 Danielson Court, Suite B
Poway, CA 92064
http://www.vetstem.com

Read the full story at http://www.prweb.com/releases/2015/08/prweb12905069.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... ... was adopted from a local shelter when he was around two years old. According ... weeks after he was adopted, he tore his right cruciate ligament. Though he had ... such a traumatic injury. , Sure enough, when Rascal was about nine years old, he ...
(Date:1/8/2019)... DENVER (PRWEB) , ... January 07, 2019 , ... ... comprised of its members into Noninvasix. This represents the second investment AngelMD has ... neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, ...
(Date:1/4/2019)... TRIANGLE PARK, N.C. (PRWEB) , ... January 04, ... ... consulting organization, is pleased to welcome Ted Hoffman to the firm. Ted will ... 20 years of experience working in and providing consulting services to the pharmaceutical ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, ... cancer, today announced the founding of a scientific and medical advisory board (SMAB). ... key leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB ...
Breaking Biology Technology:
(Date:12/18/2018)... ... December 18, 2018 , ... CP Merritt is a national champion ... for many years however in 2006, he had a medical setback that caused him ... that he suffered from cartilage degeneration in his right rear fetlock. Such an ...
(Date:12/13/2018)... ... December 13, 2018 , ... Study Protocol Summary of ... (with Ethical e-CRF®): IGA first assessment performed at the site., 3 - Three photos ... Staff Controls Photo anonymization in BOX., 5 - Photos moved to eAdjudication® and submitted ...
(Date:12/13/2018)... ... December 12, 2018 , ... Royal Biologics, an ... has announced the launch of Maxx-Cell, the world's most advanced bone marrow aspiration ... aspirating a patients autologous bone marrow cells. Maxx™-Cell however does not require centrifugation ...
Breaking Biology News(10 mins):